- Home
- MESO vs MCRI Comparison
MESO vs MCRI Comparison
Compare MESO & MCRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MESO | MCRI |
|---|---|---|
| Founded | 2004 | 1972 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | MESO | MCRI |
|---|---|---|
| Price | $18.66 | $89.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | $24.00 | ★ $100.00 |
| AVG Volume (30 Days) | ★ 214.0K | 70.8K |
| Earning Date | 02-25-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 1.33% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.41 |
| Revenue | $17,198,000.00 | ★ $539,635,000.00 |
| Revenue This Year | $576.59 | $6.34 |
| Revenue Next Year | $41.15 | $3.59 |
| P/E Ratio | ★ N/A | $20.50 |
| Revenue Growth | ★ 191.39 | 4.61 |
| 52 Week Low | $9.61 | $69.99 |
| 52 Week High | $21.50 | $113.88 |
Technical Indicators
Market Signals| Indicator | MESO | MCRI |
|---|---|---|
| Relative Strength Index (RSI) | 52.89 | 35.40 |
| Support Level | $16.67 | $88.61 |
| Resistance Level | $19.00 | $91.83 |
| Average True Range (ATR) | 0.67 | 1.94 |
| MACD | -0.07 | -0.27 |
| Stochastic Oscillator | 40.79 | 18.74 |
Price Performance
Historical ComparisonAbout MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.